Jingjing Zhang

A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.

Wei-bing Miao, Huipan Liu, Haojun Chen, 2023, European journal of nuclear medicine and molecular imaging.

Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Liang Zhao, Haojun Chen, Jianhao Chen, 2024, Signal transduction and targeted therapy.

Engineered Antibodies as Cancer Radiotheranostics

Xuejun Wen, Vivianne Jakobsson, Xiaoyuan Chen, 2024, Advanced science.

Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients.

Jun Dai, L. Xi, Ying Zhou, 2024, European journal of nuclear medicine and molecular imaging.

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

J. Cardinale, Bastian Jaeschke, E. Novruzov, 2024, Seminars in nuclear medicine.

Targeted Radionuclide Therapy in Glioblastoma.

P. Khong, Vivianne Jakobsson, Tianzhi Zhao, 2024, ACS applied materials & interfaces.

Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma.

Liang Zhao, Haojun Chen, Jianhao Chen, 2024, European journal of nuclear medicine and molecular imaging.